Drug Profile


Alternative Names: Aprozinate; Aprozinato; Promac; Z 103; ZC 103; Zinc L-carnosine

Latest Information Update: 26 May 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hamari Chemicals
  • Developer SK Chemicals; Zeria
  • Class Antiulcers; Cytoprotectives; Neuropeptides; Organometallic compounds; Small molecules
  • Mechanism of Action Lipid peroxidation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric ulcer
  • Phase III Taste disorders
  • No development reported Gastritis

Most Recent Events

  • 18 Mar 2015 No recent reports on development identified - Registered for Gastritis and Gastric ulcer in South Korea (PO)
  • 05 Feb 2015 Polaprezinc completes phase III development for Taste disorders in Japan
  • 05 Feb 2014 Polaprezinc is still in phase III trials for Taste disorders in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top